|
| 脑脊液外泌体miR-204-3p、血清外泌体lncRNA SOX21-AS1与脑胶质瘤患者术后复发的关系研究 |
| Study on the Relationship Between Cerebrospinal Fluid Exosome miR-204-3p, Serum Exosome lncRNA SOX21-AS1 and Postoperative Recurrence in Patients With Brain Glioma |
| 投稿时间：2024-07-17 修订日期：2024-07-17 |
| DOI： |
| 中文关键词: 脑胶质瘤 脑脊液外泌体 miR-204-3p lncRNA SOX21-AS1 复发 |
| 英文关键词: Brain glioma Cerebrospinal fluid exosomes miR-204-3p lncRNA SOX21-AS1 Recrudescence |
| 基金项目:河南省医学科技攻关联合共建项目（LHGJ20220676） |
|
| 摘要点击次数: 157 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：分析脑胶质瘤患者脑脊液外泌体微小RNA-204-3p（miR-204-3p）、血清外泌体长链非编码RNA细胞因子信号转导抑制因子2-反义转录本1（lncRNA SOX21-AS1）的表达以及与其术后复发的关系。方法：选取2021年8月至2023年8月于我院进行诊治的207例脑胶质瘤患者作为研究对象纳入脑胶质瘤组，另选取同期于本院进行诊治的110例颅脑损伤患者纳入颅脑损伤组；对比两组患者脑脊液外泌体miR-204-3p、血清外泌体lncRNA SOX21-AS1表达水平。对脑胶质瘤患者随访6个月，观察其术后复发情况分为复发组和未复发组。脑胶质瘤患者术后复发的影响因素采用单因素分析，术后复发的危险因素采用多因素Logistic回归分析。脑脊液外泌体miR-204-3p、血清外泌体lncRNA SOX21-AS1及联合检测对脑胶质瘤患者术后复发的预测价值采用受试者工作特征（ROC）曲线分析。结果：经术后6个月随访发现，脑胶质瘤患者有56例复发，复发率为27.05%，复发组纳入56例，未复发组纳入151例。与颅脑损伤组比较，脑胶质瘤组脑脊液外泌体miR-204-3p、血清外泌体lncRNA SOX21-AS1表达水平明显更高（P＜0.05）；肿瘤直径≥5cm、高级别胶质瘤、肿瘤未完全切除、临床分期为Ⅲ~Ⅳ期、miR-204-3p高表达和lncRNA SOX21-AS1高表达均为脑胶质瘤患者术后复发的危险因素（P＜0.05）；脑脊液外泌体miR-204-3p、血清外泌体lncRNA SOX21-AS1联合检测预测脑胶质瘤患者术后复发的曲线下面积（AUC）为0.860，优于二者单独检测。结论：脑胶质瘤患者脑脊液外泌体miR-204-3p、血清外泌体lncRNA SOX21-AS1表达水平显著升高，并且两者与患者术后复发相关，可作为脑胶质瘤患者术后复发及预后评估的标志物。 |
| 英文摘要: |
| Objective:To analyze the expression of cerebrospinal fluid exosome microRNA-204-3p (miR-204-3p) and serum exosome long-chain non-coding RNA cytokine signal transduction inhibitor 2-antisense transcript 1 (lncRNA SOX21-AS1) in patients with brain glioma and their relationship with postoperative recurrence. Methods: 207 patients with brain glioma who were diagnosed and treated in our hospital from August 2021 to August 2023 were selected as brain glioma group, and 110 patients with craniocerebral injury who were diagnosed and treated in our hospital during the same period were selected as craniocerebral injury group. The expression levels of cerebrospinal fluid exosome miR-204-3p and serum exosome lncRNA SOX21-AS1 were compared between two groups. Patients with brain glioma were followed up for 6 months, patients were divided into recurrence group and non-recurrence group according to the postoperative recurrence. The influencing factors of postoperative recurrence in patients with brain glioma were analyzed by univariate analysis, and the risk factors affecting postoperative recurrence were analyzed by multivariate Logistic regression analysis. The predictive value of cerebrospinal fluid exosome miR-204-3p, serum exosome lncRNA SOX21-AS1 and combined detection for postoperative recurrence in patients with brain glioma were analyzed by receiver operating characteristic (ROC) curve. Results: Follow followed up 6 months after operation, 56 patients with brain glioma recurred, with a recurrence rate of 27.05%, 56 patients were included in recurrence group and 151 patients were included in non-recurrence group. Compared with craniocerebral injury group, the expression levels of cerebrospinal fluid exosome miR-204-3p and serum exosome lncRNA SOX21-AS1 in brain glioma group were significantly higher(P<0.05). Tumor diameter≥5cm, high-grade glioma, incomplete tumor resection, clinical stage III-IV, high expression of miR-204-3p and high expression of lncRNA SOX21-AS1 were all risk factors for postoperative recurrence in patients with brain glioma (P<0.05). The combined detection of cerebrospinal fluid exosome miR-204-3p and serum exosome lncRNA SOX21-AS1 predicted postoperative recurrence of glioma patients with area under the curve (AUC) of 0.860, which was better than that of the two detection alone. Conclusion: The expression levels of cerebrospinal fluid exosome miR-204-3p and serum exosome lncRNA SOX21-AS1 in patients with brain glioma are significantly increased, and both are correlated with postoperative recurrence, which could be used as markers for postoperative recurrence and prognosis evaluation of patients with brain glioma. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
